In the past 12 years, we have seen an increase in new monoclonal antibodies approved by the FDA for numerous indications as treatment options for cancer, neurologic disorders, immunologic,  and autoimmune diseases, to name a few. These monoclonal antibodies are administered either subcutaneously, usually self administered by patients or administered intravenously by a registered nurse…